All News

RNL, over, microphone

RheumNow Live Preview (1.30.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from RheumNow.com - and the top 5 reasons to attend RheumNow Live 2026, which is one week away.

Read Article
synovitis2.JPG

Notch and TGFβ Signaling in Refractory Rheumatoid Arthritis

EurekAlert!

Spatial transcriptomic profiling of rheumatoid arthritis (RA) synovial biopsies (pre- and post-treatment) has revealed new insights into the pathobiology or treatment resistent RA. 

Read Article
D2T RA Cover

Difficult to Treat Rheumatoid Arthritis

Jack Cush, MD

Dr. Cush addresses the management of difficult-to-treat rheumatoid arthritis (D2TRA).

Read Article
death

Trends in Rheumatoid Arthritis Mortality

Jack Cush, MD

A recent study examines trends in rheumatoid arthritis (RA)-related mortality among U.S. postmenopausal women (aged 55 and older). They found RA mortality rates have declined, yet disparities in who is most affected persist, especially for white women, and those over 85 yrs of age.

Read Article
RheumNow Podcast square

Emergencies, Independence & Hemorrhage (1.23.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news and reports from the past two weeks on RheumNow.Com

Read Article
lung,cancer,blue,mass

BIOBADASER III Registry shows No Cancer Risk with b/tsDMARDs

Jack Cush, MD

A large, real-world cohort study of rheumatoid arthritis (RA) finds patients treated with biologic and targeted synthetic DMARDs (b/tsDMARDs) do not have an increased risk of cancer. 

Read Article
early.RA_.jpg

APPIPRA Study - Benefits of Early Treatment

EurekAlert!

Treating people who are at high risk of rheumatoid arthritis (RA) can delay the onset of the disease for several years, with benefits also continuing well after treatment has stopped.

Read Article
APR MTX Cover

Methotrexate

Jack Cush, MD

In this session, Dr. Jack Cush reviews methotrexate.

Read Article
APPIPRA Study - Benefits of Early Treatment Treating people who are at high risk of rheumatoid arthritis (RA) can delay the onset of the disease for several years, with benefits also continuing well after treatment has stopped. https://t.co/GYguq7VlqT https://t.co/5Z0BXIm3cM

Links:

Dr. John Cush RheumNow ( View Tweet)
Remission? Single center study of 100 RA, 100 SLE pts assessed by SLEDAI-2K, SDAI, VAS. Remission/LDA found in 88% of 392 SLE visits & 91% of 389 RA visits(p=NS). Remission was more common in SLE vs RA (79% vs 69%; p= 0.0018). https://t.co/ZPRrYQMsCT

Links:

Dr. John Cush RheumNow ( View Tweet)

Physical activity (PA) is assoc w/ reduced all-cause mortality in RA pts. Study of 1493 NHANES & 1724 UK Biobank RA cohorts showing robust inverse association between PA and all-cause mortality (HR: active = 0.48, highly active = 0.61) https://t.co/K6ALzqP3QQ https://t.co/2XJ0zD7FA3

Links:

Dr. John Cush RheumNow ( View Tweet)
Full read review of the Mechanistic Effects of Methotrexate in the Treatment of Rheumatoid Arthritis. https://t.co/PrMyZ7q3wX download here: https://t.co/fvEocwsXIv https://t.co/ZWVctochHV

Links:

Dr. John Cush RheumNow ( View Tweet)
Minnesota Mayo clinic retrospective, population study of RF & CCP in 1373 incident RA pts. At Dx, 37% dual seropositive, 13% +CCP only, 12% +RF only, & 38% seronegative. zDual seropositives had more erosions (31%) & flares (69% vs 51%). But +RF only highest mortality (adj 2.18) https://t.co/hPQewVgPoq
Dr. John Cush RheumNow ( View Tweet)
Clinical contributors to pathogenesis and treatment outcomes for rheumatoid arthritis. Full read review of pathogenesis and unmet needs in #RA https://t.co/OZxOuXdnIq https://t.co/LuYoLVfb7N

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheum Poll> Which is the most difficult to treat RA (D2TRA) patient (despite aggressive Rx)?

Dr. John Cush RheumNow ( View Tweet)

Testing for RF, CCP, ESR and CRP Check out the accompanying Advanced Practice Rheum: Rheumatoid and Inflammation Testing video. https://t.co/o1sle6CKg5 https://t.co/roYXcbPdBh

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheum Poll> Which is the most difficult to treat RA (D2TRA) patient (despite aggressive Rx)?

Dr. John Cush RheumNow ( View Tweet)

BIOBADASER III Registry shows No Cancer Risk with b/tsDMARDs A large, real-world cohort study of rheumatoid arthritis (RA) finds patients treated with biologic and targeted synthetic DMARDs (b/tsDMARDs) do not have an increased risk of cancer. https://t.co/0oawv88Anq https://t.co/nrsok06gKV

Links:

Dr. John Cush RheumNow ( View Tweet)
APPIPRA Study - Benefits of Early Treatment Treating people who are at high risk of rheumatoid arthritis (RA) can delay the onset of the disease for several years, with benefits also continuing well after treatment has stopped. https://t.co/hgxj936CWn https://t.co/eJX3amp3Id

Links:

Dr. John Cush RheumNow ( View Tweet)
Are JAK Inhibitors Better at Pain Relief in RA? Among rheumatoid arthritis (RA) patients who responded to upadacitinib (Rinvoq) or adalimumab, those receiving upadacitinib had significantly less residual pain with treatment, according to a post hoc analysis of phase III trial https://t.co/QrbwlxIm3d
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×